Ataroc is generally used across domains where additional symptomatic support is needed in conditions like bronchial asthma, chronic bronchitis, and pulmonary emphysema. The medication is considered relevant for easing symptoms that may become intense or disruptive in conditions such as these. The medication is applicable across conditions presenting with acute episodes, including acute bronchitis and situations involving recurrent or episodic manifestations like cough-variant asthma.

Symptomatic Relief and Functional Strain

The medication is commonly used in situations involving certain distressing symptoms linked to organ-specific functional stress. It is applied in addressing symptom clusters that interfere with daily functioning, such as pronounced wheezing, chest tightness, and acute dyspnea (difficulty breathing). The application is relevant for easing these challenging symptoms. It is relevant for managing symptoms that interfere with daily comfort. This provides support that helps ease the overall symptom burden and may assist with maintaining a sense of stability during symptomatic periods.

Regulatory References

1. FDA Verified Product Information for Procaterol

Who can and cannot use Ataroc?

This section describes official population eligibility and restriction rules for Ataroc (Procaterol), as defined by government regulatory documents.

Eligibility Scope

Use of Ataroc (Procaterol) is absolutely contraindicated in individuals with a known hypersensitivity or allergy to the active ingredient or any of the product's components.

The medicine is established for use in adults and children across various age groups. However, safety has not been established in low birth weight infants and newborns. For elderly patients, official labeling advises that dosage adjustment or other appropriate measures should be considered due to potential physiological sensitivity.

Condition-Based Restrictions

Ataroc must be administered with careful consideration and monitoring in patients with certain pre-existing conditions, including hyperthyroidism, hypertension, heart disease, and diabetes mellitus. These conditions may require close management during the course of treatment.

Pregnancy and Lactation Status

The official status for pregnancy is conditional use; administration should only occur if the expected therapeutic benefit is considered to outweigh any possible risk, as safety has not been established. For nursing mothers, the label specifies that breastfeeding must be interrupted before treatment begins.

The official interaction profile for Procaterol (Ataroc) is primarily defined by pharmacodynamic interactions related to its action as a selective beta2-adrenoceptor agonist.

Interaction-Related Restrictions

Co-administration with Catecholamines is prohibited due to the potentiation of adrenoceptor-stimulating action, which carries a documented risk of arrhythmias or cardiac arrest. Furthermore, the co-mixing of Procaterol with Benzypenicillin Potassium is avoided due to the documented physicochemical incompatibility that results in the production of white turbidity.

Pharmacodynamic Effects and Cautions

Co-administration with certain medicinal products requires caution due to recognized interaction patterns:

• beta-Adrenergic Blockers (e.g., Propranolol) may exert an antagonistic effect, which reduces the intended bronchodilatory activity of Procaterol.
• Xanthine Derivatives (e.g., Theophylline), Corticosteroids (e.g., Betamethasone), and Diuretics (e.g., Furosemide) may potentiate the risk of an aggravated decrease in serum potassium levels (hypokalemia) and increase the risk of cardiovascular adverse reactions.
• This hypokalemia risk requires extreme care when co-administering these agents in patients with severe asthma, as stated in the regulatory documentation. The same caution applies to other adrenergic drugs, including MAO Inhibitors and Tricyclic Antidepressants.

No specific interactions with food, alcohol, or herbal products are explicitly documented in the official prescribing information.

Ataroc, containing Procaterol, functions as a direct agonist selective for the beta2-adrenergic receptor (AR) subtype. The beta2-ARs are G-protein-coupled receptors predominantly expressed on smooth muscle cells within the pulmonary airways. Drug binding to the beta2-AR initiates a cascade involving the stimulatory G-protein (Gs) subunit, which subsequently activates the enzyme adenylate cyclase. This activation catalyzes the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP) within the cell cytoplasm, thereby increasing the intracellular concentration of cAMP. The elevated cAMP levels function as a second messenger, leading to the activation of protein kinase A (PKA). PKA phosphorylation of key intracellular substrates ultimately results in a reduction of intracellular calcium ion ( Ca^2+) concentration and a decrease in myosin light chain kinase activity. The molecular consequence of this cascade is the relaxation of bronchial smooth muscle, leading to a system-level increase in pulmonary airflow capacity.

How Ataroc is Used

Ataroc (Procaterol) follows specific, standardized regimens. The medication is used as an additional therapy and is not intended to substitute for primary anti-inflammatory maintenance agents such as inhaled corticosteroids.

Administration Routes and Forms

Procaterol is available for both oral administration, typically as a syrup, tablet, or dry syrup, and for delivery via inhalation, where the solution is administered using a nebulizer. The route and form chosen depend upon the specific needs and age of the patient.

Standard Dosing Regimens

Administration is generally scheduled for a once or twice daily frequency. For the adult oral dose, the standard regimen is typically 50 mcg of Procaterol hydrochloride. When administered twice daily, one dose is often taken in the morning and the second dose before bedtime to maintain consistent control. Administration of the inhalation solution is typically based on a dose of 30 to 50 µg of Procaterol per use.

Population-Specific Use and Procedural Notes

Dose adjustment or special consideration applies to specific patient populations. For older adults, appropriate measures are considered due to potential physiological sensitivity. Pediatric dosing is age-specific: children aged six years and older are typically administered 25 mcg orally, while children younger than six years receive a dose based on 1.25 mcg/kg body weight. If the desired therapeutic effect is not achieved at the recommended dose, the medication is discontinued. Oral syrup requires precise volume measurement to ensure accurate microgram dosing, particularly for weight-based regimens.

Research evidence / Overview of studies for Ataroc

Evidence for Use in Bronchial Asthma

Research involving Procaterol in bronchial asthma explored short-term, randomized controlled trials (RCTs), often using double-blind and placebo-controlled designs. These studies primarily examined outcomes related to the objective physiological functions of the airways, such as the Forced Expiratory Volume in 1 second (FEV1) and Peak Expiratory Flow Rate (PEFR). Populations evaluated included adults with chronic stable asthma and children experiencing episodic manifestations of the condition.

The studies reported that measurable changes in spirometry readings were observed, and these findings relate to symptom patterns associated with conditions characterized by fluctuating manifestations. Some short-term trials reported observations of changes in lung function measurements when compared to an inactive substance.

Evidence for Use in Chronic Obstructive Pulmonary Disease (COPD)

Research involving Procaterol in COPD has focused on controlled trials to explore the measured outcomes in conditions marked by functional limitations. These studies monitored physiological strain and examined changes in both objective measurements, like FEV1, and patient-reported outcomes describing perceived discomfort.

Studies exploring short-term symptom changes reported patterns of changes in certain physiological measurements observed in the airways. Research also examined functional outcomes, and while some trials described observed changes, other findings were mixed or did not show clear differences between treatment groups in short-term comparisons.

What Remains Uncertain and Gaps in the Research

Long-term effects on disease progression or outcomes over periods greater than a few months are not fully established by the existing research structure; most evidence is short-term. For special populations, research has explored outcomes in the pediatric population. However, specific, targeted research dedicated to senior individuals with comorbidities is limited. Furthermore, comparative evidence is lacking for many direct comparisons against the most current standard-of-care inhaled therapies used worldwide. The results apply only to the specific conditions and populations studied, and findings describe group patterns, not personal outcomes.

Key Studies & References

1. A randomized, double-blind, parallel-group, multicenter study to compare the efficacy and safety of Procaterol and Terbutaline in chronic obstructive pulmonary disease
2. Clinical Practice Guideline for the Management of Asthma: Summary of Evidence Review for Bronchodilator Agents

Common questions about Ataroc (FAQ)

Q: What is Ataroc used for besides its main listed purpose?

Official indications for Procaterol often include the treatment and maintenance of symptoms associated with chronic respiratory conditions. These conditions include bronchial asthma, chronic bronchitis, and pulmonary emphysema.

Q: Is Ataroc a controlled substance?

Official product information classifies Procaterol as a prescription-only medicine. It is important to note that the drug is generally not listed or classified as a controlled substance, unlike some narcotic or high-dependency medications.

Q: How quickly is Ataroc supposed to start working?

Official product information indicates that for the oral form of Procaterol, the intended effect (bronchodilation) typically begins within 30 minutes of administration. The full or peak effect is generally seen between one and a half to three hours after the dose is taken.

Q: Can Ataroc be taken long-term?

Studies examining the effects of Procaterol have explored its use over periods of up to 52 weeks in certain patient populations, such as those with stable Chronic Obstructive Pulmonary Disease (COPD). The official documentation regarding long-term safety and effectiveness relies on data from these types of clinical trials.

Q: Is Ataroc the same as [Name of common similar drug]?

Ataroc is the trade name for the specific chemical compound Procaterol. This drug belongs to the pharmacological class of selective beta2-adrenoceptor agonists (bronchodilators). It is a unique chemical entity and is not the same as other respiratory medicines in the same class.

Q: Is Ataroc safe to take with alcohol?

According to the official prescribing information, there are no specific interactions documented between the active ingredient Procaterol and alcohol. The regulatory documentation primarily focuses on known drug-to-drug interactions.

Q: Do I need to eat food when taking Ataroc?

Official administration instructions for oral forms of Procaterol, such as the tablet, state that they may generally be taken with or without food. This means taking it alongside a meal is typically not required to ensure the drug works correctly.

Q: Can Ataroc affect sleep patterns?

The official safety profile for Procaterol lists insomnia (difficulty falling or staying asleep) as a potential adverse reaction. It is generally noted as an uncommon side effect.

Q: Is Ataroc safe for use in older adults?

Official documentation indicates that no overall difference in efficacy or safety has been observed between older and younger patients. However, the regulatory guidance advises that dosage adjustment or appropriate clinical measures should be considered for older individuals due to potential physiological changes.

Q: Can Ataroc interact with over-the-counter medications?

Official regulatory documents describe interactions based on broad drug classes, such as beta-adrenergic blockers and Xanthine derivatives. The official profile for Procaterol lists these specific classes.

Q: How long does the effect of Ataroc usually last?

According to the official product information, the bronchodilating effect of Procaterol is reported to last for approximately 8 hours following a single dose. This duration informs the standard frequency of administration.

Q: Does Ataroc show up on standard drug tests?

Procaterol is classified as a beta2-Agonist. This class of drugs is specifically listed on anti-doping agency prohibited lists for use in competitive sports. The regulatory status of the drug may lead to positive results on certain specialized drug screenings, especially in sports settings.

Q: Is there a generic version of Ataroc available?

The active ingredient in Ataroc is Procaterol. The medication is sold under various brand names internationally, and generic formulations of Procaterol may be available in some regions, depending on the local market regulations.

Q: Does Ataroc affect blood pressure?

Official product information suggests that, due to the drug's mechanism of action, monitoring of heart rate and blood pressure may be recommended at the start of treatment and periodically throughout its course.

Q: Is Ataroc safe for people with kidney issues?

The safety profile for Procaterol notes a specific interaction risk involving the renal tubules (part of the kidneys). Co-administration with diuretics can increase the excretion of potassium, which may result in a decrease in serum potassium levels.

Q: Are there different strengths of Ataroc available?

Official documents indicate that the medication is available in multiple forms and different strengths to suit various populations. These formulations include oral tablets for systemic use and inhalation solutions for local delivery.

Q: Does Ataroc interact with common supplements like Vitamin D or magnesium?

Official regulatory documents primarily list pharmacodynamic interactions with prescribed drug classes like beta-blockers. They do not typically contain explicit information documenting interactions with common non-herbal dietary supplements like Vitamin D or magnesium.

Q: Is it true that Ataroc is being researched for new uses?

Clinical research and trials have investigated the use of Procaterol in specific, related respiratory conditions, such as Cough Variant Asthma (CVA). This suggests that the use of the drug may be explored beyond its initial listed indications.

Q: How does Ataroc compare to [Name of another similar drug] in its class?

Regulatory documents describe Procaterol as a selective beta2-adrenoceptor agonist. It is characterized by having a higher selectivity for receptors in the respiratory system compared to those in the cardiovascular system, which distinguishes it from older, less specific medications in the same class.

Q: Are there any reported long-term safety concerns with Ataroc?

Official safety information advises that taking excessive amounts of Procaterol continuously carries a documented risk of serious cardiac issues, specifically tachycardiac arrhythmia and cardiac arrest. This warning relates to inappropriate, high-dose exposure over time.

Q: Can Ataroc be taken with pain relievers like ibuprofen?

Regulatory interaction information indicates that Procaterol is known to interact with certain medications in the class of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). This co-administration may carry an increased risk of elevated blood pressure (hypertension).

Q: How long after stopping Ataroc will it be out of my system?

Regulatory documents describing the pharmacokinetic profile note that following inhalation, the drug is eliminated from the body by a gradual decline from a peak plasma concentration.

Q: Does Ataroc require special monitoring by a doctor?

Official safety information specifies that careful consideration and close management are advised for individuals who have certain pre-existing conditions. These conditions often include heart disease, hypertension, hyperthyroidism, and diabetes mellitus in these populations.

Q: Are there any warnings about driving or operating machinery while on Ataroc?

The safety profile lists side effects such as dizziness and headache as uncommon adverse reactions. These effects are noted because they could potentially impair a person's ability to drive safely or operate complex machinery.

Q: Can Ataroc be used by people with liver conditions?

Clinical trial documentation indicates that patients with severe hepatic (liver) disease have often been excluded from studies of Procaterol. This exclusion is noted due to the medication’s known effects on hepatic enzymes.

Q: Is Ataroc approved by the FDA?

According to international drug status information, the active ingredient Procaterol is not currently approved for commercial use in the United States by the Food and Drug Administration (FDA). The product’s availability is primarily in other countries with their own regulatory bodies.

How to Store and Dispose of Ataroc (Procaterol)

The official storage and disposal requirements for Ataroc (Procaterol) are mandated to ensure product quality and public safety.

Storage Requirements

• Temperature and Light: The medicine must be stored at a temperature not exceeding 30°C and must be protected from light. Liquid forms (syrup, inhalant solution) must be protected from freezing and excessive heat.
• Packaging: Ataroc must be kept in its original container with the container tightly closed to prevent moisture and degradation.
• Child Safety: All forms must be stored out of the sight and reach of children.
• Stability: Once liquid formulations are opened, they have a limited in-use shelf life, often requiring disposal after a set period (e.g., 28 days).

Disposal Instructions

Expired or unused Ataroc must not be thrown away with household trash or flushed down the toilet (wastewater). Disposal must adhere to local regulations, typically by returning the product to a pharmacist or a designated pharmaceutical waste collection program.